Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GE Acquires Strategic Assets from Thermo

Published: Monday, January 06, 2014
Last Updated: Monday, January 06, 2014
Bookmark and Share
GE to acquire cell culture media and sera, gene modulation and magnetic beads businesses.

GE and Thermo Fisher Scientific announced that they have entered into an agreement for GE Healthcare to acquire Thermo Fisher’s HyClone™ cell culture media and sera, and gene modulation and magnetic beads businesses for approximately $1.06 billion.  The acquisition will allow GE to expand its offering of technologies for the discovery and manufacturing of innovative new medicines, vaccines and diagnostics in its growing Life Sciences business.  

The complementary product offerings and strong strategic fit of the acquired businesses will enable GE Healthcare to expand and accelerate the development of innovative “end-to-end” technologies for cell biology research, cell therapy and for the manufacture of innovative biological medicines and vaccines.  The acquisition is consistent with GE’s strategy to invest in high-technology, innovative businesses that deliver strong top-line growth and expanded margins. GE’s acquisition of the businesses, which is subject to regulatory approvals, is anticipated to close in the first part of 2014.  

GE Healthcare’s century of leadership in medical diagnostic technology includes its $4 billion Life Sciences business, which delivers innovative products and services for the fast-growing diagnostics, research and biopharmaceutical manufacturing sectors.

John Dineen, President and CEO, GE Healthcare said, “Life Sciences is one of our strongest and fastest-growing business areas, driven by the world’s demand for improved diagnostics and new, safer medicines.  Combining GE’s engineering expertise with our capabilities in life sciences is already bringing great benefits to industry, research and patients.  This deal makes a good business even better and will help us realize our vision of bringing better healthcare to more people at lower cost.”

Cell culture plays a key role in manufacturing medicines to treat diseases such as cancer and rheumatoid arthritis, as well as a new generation of vaccines.  Thermo Fisher’s well-respected HyClone™ cell culture media and sera products are highly complementary to GE Healthcare’s established technologies for cell biology research and biopharmaceutical manufacturing, enabling GE to offer its customers a substantially wider range of technologies and services.

GE Healthcare will also acquire Thermo Fisher’s gene modulation technologies, which strongly complement GE’s established technologies for drug discovery research, and the innovative Sera-Mag™ magnetic beads product line, which extends GE’s existing technologies in protein analysis and medical diagnostics.

Kieran Murphy, President and CEO of GE Healthcare’s Life Sciences division said, “We look forward to the HyClone cell culture and other businesses joining the GE family.  They are a great fit with our key areas of focus, and bring exciting new technologies, enhanced manufacturing capabilities as well as a great group of talented people to help grow our business.” 

“In addition to providing us with new approaches to drug discovery and biomedical research,” Murphy said, “this acquisition is a significant step forward for our customers in biopharmaceutical manufacturing.  They will benefit immediately from an expanded range of “start-to-finish” technologies that will help them improve product yields and reduce time-to-market. By expanding our production facilities to three continents, we will be able to offer the biopharmaceutical industry greater confidence in the security of supply of cell culture media and sera, a key part of their production process.”

The three acquired businesses generated combined annual revenues of approximately $250 million in 2013.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GE Healthcare Expands European Capabilities
Expansion will see large volume sterile liquid handling capacity doubled.
Tuesday, April 12, 2016
BeiGene Selects GE’s FlexFactory™ Biomanufacturing Platform
Facility will manufacture biologics for clinical trials.
Wednesday, December 16, 2015
GE Healthcare Licenses CRISPR Gene Engineering Technology Patents
Agreement will drive bioscience research by enabling development of novel Dharmacon genome engineering toolsets.
Tuesday, December 09, 2014
GE Licenses CRISPR Gene Engineering Technology Patents From Broad Institute
Agreement will drive bioscience research by enabling development of novel Dharmacon genome engineering toolsets.
Thursday, December 04, 2014
GE Healthcare and Takeda Join Forces
This alliance is key to enabling the early development of therapeutic drugs through the use of a minimally invasive diagnostic technology.
Thursday, November 13, 2014
GE Healthcare to Collaborate with GlaxoSmithKline on Commercial Oncology Testing
The collaboration aims to improve access to diagnostic testing for cancer patients by establishing a network of clinical laboratories to identify genetic mutations associated with different tumour types.
Tuesday, September 30, 2014
GE Healthcare Life Sciences and Promosome Sign Licensing Agreement
Innovative mammalian cell line development technologies that show promise for increasing manufacturing efficiency of vital biopharmaceuticals.
Tuesday, April 29, 2014
GE Healthcare Acquires Unisyn Medical Technologies’ Transactional Business
The proprietary products and services from Unisyn will be integrated into GE Healthcare’s Global Services organization.
Thursday, May 30, 2013
Winners of GE Healthcare 2012 Cell Imaging Competition Announced
Stunning cellular images to light up Times Square, New York.
Thursday, February 28, 2013
GE Healthcare Launches Modular Biopharmaceutical Factory, KUBio
Innovative approach will save biopharmaceutical manufacturers time and money.
Tuesday, January 15, 2013
iBio, Inc. and GE Healthcare Form New Global Alliance
Companies to commercialize plant-based technologies for biopharmaceutical and vaccine manufacture.
Thursday, December 27, 2012
GE Healthcare’s 2012 Cell Imaging Competition - Voting Opens to Celebrate Art, Science and Discovery
Competition features both high-content analysis and high- and super-resolution microscopy cell images for the first time.
Thursday, November 22, 2012
GE Healthcare Scientist Paired with Cardiff MP to Share Insights on Cell Therapy, Science and Policy-Making
Dr. Michelle Janas from GE Healthcare Life Sciences visited Jenny Willott MP at the House of Commons for a “Week in Westminster” as part of a unique ‘pairing’ scheme run by the Royal Society.
Thursday, November 15, 2012
GE Healthcare Expands Shanghai Fast Trak Training Center
Expansion adds IN Cell, Biacore and DeltaVision technologies for drug discovery and development.
Monday, September 24, 2012
GE Healthcare Offers Fast Trak Training in Singapore
Fast Trak training and education courses provide practical training in the latest technologies and strategies for bioprocessing.
Tuesday, June 05, 2012
Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Apricot Kernels Pose Risk of Cyanide Poisoning
Eating more than three small raw apricot kernels, or less than half of one large kernel, in a serving can exceed safe levels. Toddlers consuming even one small apricot kernel risk being over the safe level.
Cell Transplant Treats Parkinson’s in Mice
A University of Wisconsin—Madison neuroscientist has inserted a genetic switch into nerve cells so a patient can alter their activity by taking designer drugs that would not affect any other cell.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Genetic Markers Influence Addiction
Differences in vulnerability to cocaine addiction and relapse linked to both inherited traits and epigenetics, U-M researchers find.
Lab-on-a-Chip for Detecting Glucose
By integrating microfluidic chips with fiber optic biosensors, researchers in China are creating ultrasensitive lab-on-a-chip devices to detect glucose levels.
A lncRNA Regulates Repair of DNA Breaks in Breast Cancer Cells
Findings give "new insight" into biology of tough-to-treat breast cancer.
COPD Linked to Increased Bacterial Invasion
Persistent inflammation in COPD may result from a defect in the immune system that allows airway bacteria to invade deeper into the lung.
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!